Acetyl-L-carnitine undervalued in the treatment of chemotherapy-induced peripheral neuropathy?

References

• Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013;63:419–37.
   PubMed Web of Science ®Google Scholar
• Ezendam NP, Pijlman B, Bhugwandass C, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol 2014;135:510–7.
   PubMed Web of Science ®Google Scholar
• Mols F, Beijers T, Lemmens V, et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013;31:2699–707.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:1941–67.
   PubMed Web of Science ®Google Scholar
• Reuter SE, Evans AM. Carnitine and acylcarnitines: pharmacokinetic, pharmacological and Clinical Aspects. Clin Pharmacokinet 2012;51:553–72.
   PubMed Web of Science ®Google Scholar
• Ribas GS, Vargas CR, Wajner M. L-carnitine supplementation as a potential antioxidant therapy for inherited neurometabolic disorders. Gene 2014;533:469–76.
   PubMed Web of Science ®Google Scholar
• Flatters SJ, Xiao WH, Bennett GJ. Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett 2006;397:219–23.
   PubMed Web of Science ®Google Scholar
• Ghirardi O, Lo Giudice P, Pisano C, et al. Acetyl-L-Carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res 2005;25:2681–7.
   PubMed Web of Science ®Google Scholar
• Pisano C, Pratesi G, Laccabue D, et al. Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003;9:5756–67.
   PubMed Web of Science ®Google Scholar
• Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006;122:245–57.
   PubMed Web of Science ®Google Scholar
• Zheng H, Xiao WH, Bennett GJ. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011;232:154–61.
   PubMed Web of Science ®Google Scholar
• Lawenda BD, Kelly KM, Ladas EJ, et al. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 2008;100:773–83.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 2005;41:1746–50.
   PubMed Web of Science ®Google Scholar
• Maestri A, De Pasquale Ceratti A, Cundari S, et al. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005;91:135–8.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Unger JM, Crew KD, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 2013;31:2627–33.
   PubMed Web of Science ®Google Scholar
• Callander N, Markovina S, Eickhoff J, et al. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol 2014;74:875–82.
   PubMed Web of Science ®Google Scholar
• Campone M, Berton-Rigaud D, Joly-Lobbedez F, et al. A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. Oncologist 2013;18:1190–1.
   PubMed Web of Science ®Google Scholar
• Ellithy M, Ghali R, Elghamry W, et al. The effect of acetyl-L-carnitine in reducing the taxanes induced neuropathy. Neuro-Oncology 2014;16:ii58. English.
   Web of Science ®Google Scholar
• Sun Y, Liu B, Liu P, et al. A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine (ALC) in treatment of chemotherapy-induced peripheral neuropathy (CPIN). J Clin Oncol 2012;30:9017. English.
   Web of Science ®Google Scholar
• Malaguarnera M, Risino C, Gargante MP, et al. Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World J Gastroenterol 2006;12:4541–5.
   PubMed Web of Science ®Google Scholar
• Rogalidou M, Evangeliou A, Stiakaki E, et al. Serum carnitine levels in childhood leukemia. J Pediatr Hematol Oncol 2010;32:e61–9.
   PubMed Web of Science ®Google Scholar
• Yaris N, Akyuz C, Coskun T, et al. Serum carnitine levels of pediatric cancer patients. Pediatr Hematol Oncol 2002;19:1–8.
   PubMed Web of Science ®Google Scholar
• Heuberger W, Berardi S, Jacky E, et al. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol 1998;54:503–8.
   PubMed Web of Science ®Google Scholar
• Mancinelli A, D'iddio S, Bisonni R, et al. Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. Cancer Chemother Pharmacol 2007;60:19–26.
   PubMed Web of Science ®Google Scholar
• Marthaler NP, Visarius T, Kupfer A, et al. Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother Pharmacol 1999;44:170–2.
   PubMed Web of Science ®Google Scholar